The Federal Court's decision between AbbVie Biotechnology Ltd. v. The Attorney General of Canada, 2014 FC 1251, has resulted in the Canadian Patent Office issuing a revision to the practice guidelines for the examination of patent applications with medical use claims, particularly in the area of dosage regimens or dosage ranges. For more information please click here.
We are a Patent and Trademark Agency specializing in obtaining patents, trademarks and designs in Canada for foreign associates and corporations.
No comments:
Post a Comment